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ABSTRACT
Several extrahepatic diseases have been associated with chronic hepatitis C virus (HCV) infection (i.e. hematologic dis-
eases, renal disease, dermatologic conditions). It has also been shown that HCV infection is associated with increased 
incidence of clinical and subclinical autoimmune thyroid disorders. Moreover, interferon (IFN)-α therapy of chronic HCV 
infection is associated with subclinical or clinical thyroiditis in up to 40% of cases. Interferon induced thyroiditis (IIT) can 
be classified as autoimmune type and non-autoimmune type. Current studies indicate that viral load, viral genotype and 
therapeutic regimen do not influence development of IIT in chronic hepatitis C patients thus, and development of IIT is 
not a predictor of sustained viral response. However, evidence suggests that genetic factors, gender, HCV infection and 
positivity of thyroid antibodies may play role. J Microbiol Infect Dis 2013; 3(3): 147-149
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Hepatit C veya interferon tedavisi ile ilişkili tiroit hastalıkları
ÖZET
Karaciğer dışı birçok hastalık kronik hepatit C virüs (HCV) enfeksiyonu (hematolojik hastalıklar, böbrek hastalığı, der-
matolojik problemler) ile ilişkilendirilmiştir. HCV enfeksiyonunun klinik ya da subklinik oto-immün tiroid hastalıklarının 
artmış insidansıyla da ilişkili olduğu gösterilmiştir. Ayrıca, kronik HCV enfeksiyonunun interferon (IFN)-α ile tedavisi 
vakaların % 40’ına kadar olan kısmında subklinik veya klinik tiroidit ile ilişkilidir. İnterferon ilişkili tiroidit (İİT), otoimmün 
tip ve otoimmün olmayan tip olarak sınıflandırılabilir. Mevcut çalışmalar viral yük, viral genotip ve tedavi rejiminin kro-
nik hepatit C hastalarında İİT gelişimini etkilemediğini, ayrıca İİT gelişmesinin kalıcı viral yanıt (KVY) için bir gösterge 
olmadığını, ancak, genetik faktörler, cinsiyet, HCV enfeksiyonu ve tiroid antikor (TAb) pozitifliğinin rol oynayabileceğini 
göstermektedir.
Anahtar kelimeler: Hepatit C, interferon, tiroid hastalıkları
Hepatitis C infection and thyroid disorders
Several extra hepatic diseases have been associ-
ated with chronic hepatitis C (HCV) infection includ-
ing hematologic diseases such as cryoglobulinemia 
and lymphoma, renal disease, dermatologic condi-
tions (lichen planus and porphyria cutanea tarda).1 
Chronic HCV infection has also been demonstrated 
to be associated with clinical and subclinical auto-
immune thyroiditis (i.e. the presence of thyroid anti-
bodies in euthyroid subjects).2,3 Two studies are im-
portant in this field. A large and well-controlled study 
showed that the prevalence of both hypothyroidism 
and thyroid autoimmunity were significantly higher 
in patients with hepatitis C compared to controls.3 
The other study strengthened further the evidence 
for this association which found that the prevalence 
of non-autoimmune hypothyroidism, as well as 
the presence of anti-thyroglobulin antibodies, was 
higher in untreated children with HCV compared 
to children without HCV infection. This increased 
prevalence was not found to be related other pa-
rameters (family history of autoimmune diseases, 
duration of HCV infection, viral genotype, viral load 
or liver function) except active HCV infection.4 In ad-
dition, analyzing of all published controlled studies 
on HCV infection and thyroid autoimmunity resulted 
a significant increase in the risk of thyroiditis in HCV 
patients. This implies that, HCV infection is the only 
infectious agent that is clearly associated with an 
increased risk for autoimmune thyroiditis.2 It is pos-
sible that HCV induce thyroid autoimmunity in ge-
netically susceptible individuals by interacting with 
genetic risk factors. However, the biologic mecha-
nisms of such interactions is not known yet.6Barut Ş and Günal Ö. Thyroid disorders, hepatitis C and interferon therapy 148
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Interferon based therapies and thyroid disorders
According  to  current  medical  practice,  interferon 
(IFN)-α  or  pegylated  IFN--α  is  fundamental  for 
chronic hepatitis C treatment.7  Moreover,  IFN-α 
therapy for chronic HCV infection is associated 
with subclinical or clinical thyroiditis in up to 40% 
of cases and, IFN-α is one of the most important 
environmental triggers of autoimmune thyroid dis-
ease (AITD).2 Interferon induced thyroiditis (IIT) can 
be classified as autoimmune type and non-autoim-
mune type.7
i. Autoimmune IIT: The entire spectrum of AITD 
has  been  defined  with  the  results  of  patients  re-
ceiving IFN-α: Graves’ disease (GD), Hashimoto’s 
thyroiditis (HT) and the presence of thyroid anti-
bodies (TAb’s) without clinical disease.7 HT is the 
most common clinical manifestation of autoimmune 
IIT whereas Grave’s disease (GD) is a less com-
mon clinical manifestation.8 HT develops commonly 
in patients having positive TAb before they receive 
IFN-α. Besides, HCV patients receiving INF-α may 
also develop HT as de novo although they did not 
have positive TAb prior to therapy. These data im-
plies that genetic susceptibility may be an underly-
ing factor for the development of AITD after receiv-
ing IFNa.2,7 Subclinical AITD, which is characterized 
by production of TAb without clinical disease, may 
also develop during IFN-α therapy. De novo devel-
opment of TAb is seen in approximately 10-40% of 
cases.7,8
ii. Non-autoimmune IIT: Non-autoimmune IIT is 
also common like autoimmune IIT. It can manifest 
as destructive thyroiditis, with early thyrotoxicosis 
and later hypothyroidism, or as non-autoimmune 
hypothyroidism. In most cases of destructive thy-
roiditis, subclinical thyroid dysfunction and spon-
taneous resolution mainly occurred. The negative 
TSH-receptor  antibodies  (TRAb)  and  low  thyroid 
radioactive iodine uptake are the base for the di-
agnosis of destructive thyroiditis in patients receiv-
ing interferon therapy.7,8 The destructive form of IIT 
is theorized as being secondary non-autoimmune 
thyroid inflammation.7 Thus, this type of thyroiditis is 
mainly due to direct effect of IFN on thyroid gland. 
The differentiation of autoimmune thyroiditis from 
non-autoimmune IIT can be mainly based on test-
ing thyroid auto-antibodies (anti-TPO or thyroglobu-
lin antibodies) which are characteristics of autoim-
mune IIT.
Epidemiologic studies related to IIT
Danilovic et al.9 prospectively selected 26 patients 
with chronic HCV infections to investigate thyroid 
disturbances induced by IFN-α and ribavirin thera-
py. Of all patients, 54% had no thyroid disorders as-
sociated with the IFN-α therapy. Nineteen percent 
of the subjects had autoimmune IIT characterized 
by development of anti-thyroid antibodies or overt 
hypothyroidism. Additionally, 16% had non-autoim-
mune thyroiditis, which characterized by destructive 
thyroiditis or subclinical hypothyroidism, and 11% of 
patients who had TAb’s prior to therapy remained 
in a state of euthyroidism.9 In a recent study from 
Turkey showed that de novo incidence of thyroid 
dysfunction  (TD)  was  found  to  be  16.8%  among 
the 119 chronic HCV patients receiving pegylated-
interferon plus ribavirin.10 Similarly, a clinical study 
also showed that 11.5% of patients developed TD, 
85.3% of these patients presented with subclinical 
TD, and 14.7% of them developed overt thyroiditis, 
at the end of the IFN-α based therapy. The study 
also showed that 67.8% of them the thyroid function 
spontaneously returned to normal in the six months 
of follow-up and only 4.4% had persistent overt TD 
symptoms after the 24 month follow-up period.11 
The likelihood of TD development during the treat-
ment varies between 5.5% and 27.8% according to 
different studies.1,10,12,14
Factors associated with IIT
There are various factors that predisposed patients 
with HCV to IIT. There is a genetic susceptibility to 
IIT.2,7 A specific pretreatment risk factor, presence of 
TPO-Ab, has also been shown to be a statistically 
significant risk factor for developing thyroid disease 
in patients treated with IFN.8,10 Watanabe et al.15 
reported that the incidence of thyroid diseases in 
patients with baseline positive TPO-Ab was much 
higher than that of patients with negative TPO-Ab 
levels (60% vs. 3.3). Roti et al.16 demonstrated that 
elevated TPO antibodies before IFN-α therapy had 
a positive predictive value of 67% for the develop-
ment of clinical autoimmune IIT. We also found that 
anti-TPO positivity was the only significant predic-
tor of thyroid disorder during IFN based therapy of 
chronic hepatitis C in logistic regression analysis 
in our previous clinical study.10 Similarly a study 
performed among the 592 Chinese patients who 
received IFN-α based therapy for chronic HCV in-
fection demonstrated that gender and pretreatment 
TPO-Ab  were  the  independent  factors  related  to 
the incidence of TD.11 Therefore, it is recommended 
that patients with baseline TAb’s should be followed 
more closely for thyroid dysfunction while on IFN-α 
therapy.7
Various risk factors for IIT have been evaluat-
ed. Although a recent study reported a positive and 
significant association between thyroid disease and Barut Ş and Günal Ö. Thyroid disorders, hepatitis C and interferon therapy 149
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viral clearance, our previous study together with the 
study of Vezali et al.13 demonstrated that virologi-
cal factors such as early virologic response or sus-
tained viral response (SVR) as well as the type of 
IFN- α were not associated with IFN induced thyroid 
dysfunction in chronic HCV patients receiving pe-
gylated-IFN plus ribavirin.10,17 Vezali and coworkers13 
evaluated the 94 chronic HCV patients (61 patients 
treated  with  pegylated-IFN-α  plus  ribavirin  vs. 33 
untreated chronic HCV patients) in long time period 
for TD. The control group patients remained euthy-
roid (P <0.001) and 13 (21.3%) out of 61 treatment 
group patients experienced TD. Eleven of this 13 
patients were diagnosed with hypothyroidism and 
2 of them with hyperthyroidism that later converted 
to hypothyroidism. The incidence of TD in women 
(9 of 13, 69.2%) was higher than the incidence of 
TD in men (4 of 13, 30.8%), however the difference 
was  not  statistically  significant  (P  =0.122).  More-
over, 10 (16.4%) of 61 treated patients developed at 
least one and more autoimmune disease during the 
course of therapy (4 psoriasis, 2 mixed cryoglobuli-
nemia, 2 rheumatoid arthritis-like syndrome, 1 lichen 
planus and 1 idiopathic-thrombocytopenia). The 
authors noted that 13 independent variables were 
potentially associated with TD including sex, age, 
body mass index, HCV genotype, pretreatment viral 
load, treatment regimen and duration, total dose of 
pegylated-IFN-α and ribavirin, and SVR. However 
TD could not be predicted with any of these. The 
only correlation declared by that study was the re-
lationship between TD development and the onset 
of other autoimmune disorders during combination 
therapy (P=0.003).13
In conclusion, both HCV itself and IFN-α ther-
apy have been found to be inducing thyroid disor-
ders in patients with HCV infection. Autoimmune or 
non-autoimmune thyroiditis can occur during IFN-α 
based treatment. Studies indicate that viral load, 
viral genotype and therapeutic regimen do not in-
fluence development of IIT in chronic HCV patients 
thus, and development of IIT is not a predictor of 
SVR. However, evidence suggests that genetic fac-
tors, gender, HCV infection and positivity of TAb’s 
may play a role. Thyroid function tests and TAb’s 
should be screened before treatment and also thy-
roid function tests should be monitored during ther-
apy regularly.
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